Who are Sincalide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Caerulein, Peptavlon, D-Loxiglumide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sincalide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sincalide — Competitive Intelligence Brief

Sincalide (SINCALIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholecystokinin Analog [EPC]. Area: Gastroenterology.

marketed Cholecystokinin Analog [EPC] Cholecystokinin receptor type A Gastroenterology Recombinant protein Live · refreshed every 30 min

Target snapshot

Sincalide (SINCALIDE) — Bracco. Sincalide works by binding to cholecystokinin receptors in the pancreas, stimulating the release of digestive enzymes.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sincalide TARGET	SINCALIDE	Bracco	marketed	Cholecystokinin Analog [EPC]	Cholecystokinin receptor type A	1976-01-01
Caerulein	CERULETIDE		marketed	ceruletide	Cholecystokinin receptor type A	1982-01-01
Peptavlon	PENTAGASTRIN		marketed	pentagastrin	Gastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor	1974-01-01
D-Loxiglumide	DEXLOXIGLUMIDE		phase 3	dexloxiglumide	Cholecystokinin receptor type A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-04-20 — Sincalide · 11737983 · Formulation · US
2038-04-20 — Sincalide · 11318100 · Formulation · US
2038-04-20 — Sincalide · 11110063 · Formulation · US

Sponsor landscape (Cholecystokinin Analog [EPC] class)

Bracco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sincalide — Competitive Intelligence Brief. https://druglandscape.com/ci/sincalide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab